Immutep vs NewAmsterdam Pharma
IMMP and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMMP and NAMS compare
Immutep grew revenue faster over the last twelve months (134% versus −26.4% for NewAmsterdam Pharma).
Immutep keeps more of each dollar of sales as profit, with a net margin of −328% compared with −790% at NewAmsterdam Pharma.
Immutep scores higher on the StockData Score (8 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMMP | NAMS |
|---|---|---|
| Size and price | ||
| Share price | $3.48 | $20.14 |
| Change, 1 year | −90.3% | −47.4% |
| Change, 5 years | −95.4% | 105% |
| Beta (5Y) | 1.67 | 0.83 |
| Employees | 46 | 100 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 134% (better) | −26.4% |
| Revenue growth, 5Y average | 43.5% | – |
| Profitability | ||
| Operating margin | – | −900% |
| Net margin | −328% (better) | −790% |
| FCF margin | −230% (better) | −582% |
| Return on equity | −77.3% | −30.2% (better) |
| Return on invested capital | – | −1333% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.69 | 11.76 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Ownership | ||
| Held by insiders | 0.89% | 22.0% |
| Insider net buying, 12 months | – | −$63.0M |
Go deeper
- IMMP stock overview
- IMMP income statement
- IMMP valuation and score
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.